MENLO PARK, Calif.,
March 20, 2017 /PRNewswire/
-- Forty Seven Inc., a clinical-stage immuno-oncology company
announced today that Mark A.
McCamish, M.D., Ph.D., will join the company on May 1 as President and CEO.
Dr. McCamish, who was most recently Global Head of
Biopharmaceutical Development at Sandoz Inc., succeeds the founding
CEO, Jonathan MacQuitty, Ph.D. Dr.
MacQuitty, who is now a Venture Partner at Lightspeed Venture
Partners, will remain on the company's Board of Directors.
"Forty Seven has made unprecedented progress to date based on
the remarkable science initiated by the world-class efforts of Dr.
Irv Weissman and Dr. Ravi Majeti and their combined team at
Stanford University. In addition,
Jonathan MacQuitty has assembled an amazing team at the company,"
said Dr. McCamish. "Forty Seven's technology provides a unique
opportunity to harness the power of the innate immune system to
help patients defeat their own cancer."
Jonathan MacQuitty said, "Mark has demonstrated exceptional
leadership capabilities, as well as a unique combination of
late-phase biological drug development, scientific understanding,
and a passion for patient benefit that will lead Forty Seven into
the future."
Mark has been an executive at several companies including
Abbott Labs, Amgen, and PDL
Biopharma. Most recently he helped pioneer global biosimilar
development at Novartis' Sandoz division. Mark led the Sandoz team
at the first ever US FDA Oncology Drug Advisory Committee
evaluation of a biosimilar (filgrastim) resulting in a unanimous
endorsement and followed that by obtaining a unanimous endorsement
of Sandoz' second US biosimilar (etanercept) by the US FDA
Arthritis Advisory Committee. Under his guidance, Sandoz
Biopharmaceuticals Development has emerged as a leader in the field
having filed several BLA's through September
2016, when Mark retired from Sandoz.
About Forty Seven Inc.
Forty Seven Inc. is a clinical-stage immuno-oncology company
that is developing therapies licensed from Stanford University targeting cancer immune evasion
pathways. The lead program Hu5F9-G4 is a monoclonal antibody
against the CD47 receptor, a "don't eat me" signal that cancer
cells commandeer to avoid being ingested by the immune system. This
antibody is currently being evaluated in four Phase 1 clinical
studies in the US and the UK in patients with solid tumors or
cutaneous T-cell lymphoma (CTCL), acute myeloid leukemia (AML),
non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC).
Forty Seven is located at 1490 O'Brien Drive, Suite A,
Menlo Park, CA 94025, U.S.A.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/forty-seven-inc-announces-mark-mccamish-md-phd-to-join-as-ceo-on-may-1st-300426601.html
SOURCE Forty Seven Inc.